+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Ovarian Cancer Diagnostics Market by Cancer Type, Diagnosis Type, End-User - Global Forecast 2025-2030- Product Image
Ovarian Cancer Diagnostics Market by Cancer Type, Diagnosis Type, End-User - Global Forecast 2025-2030- Product Image
Sale

Ovarian Cancer Diagnostics Market by Cancer Type, Diagnosis Type, End-User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 190 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5674412
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Ovarian Cancer Diagnostics Market grew from USD 7.17 billion in 2023 to USD 8.18 billion in 2024. It is expected to continue growing at a CAGR of 14.50%, reaching USD 18.50 billion by 2030.

The scope of the ovarian cancer diagnostics market encompasses the assessment, detection, and monitoring of ovarian cancer, with a definition centered around diverse diagnostic tools such as imaging techniques, genetic testing, and biomarker assays. The necessity for advancements in this market is driven by the high mortality rate associated with ovarian cancer, underscoring the critical demand for early and accurate diagnosis. The application of these diagnostics is primarily within healthcare settings like hospitals and diagnostic labs, while end-use spans clinicians, researchers, and patients seeking preventative and therapeutic interventions. Key factors influencing growth include increasing awareness and incidence of ovarian cancer, technological advancements, and improved healthcare infrastructure. Governments and organizations supporting oncology research financially also catalyze market expansion. Notably, the integration of artificial intelligence and machine learning for predictive analytics in diagnostic procedures presents a significant opportunity for stakeholders. However, market growth is constrained by high costs associated with advanced diagnostic tests, limited accessibility in developing regions, and regulatory challenges that slow new product introductions. Potential innovations lie in developing non-invasive diagnostic tests, enhancing biomarker discovery for more precise diagnostics, and improving personalized medicine approaches. Continued research into gene editing technologies and liquid biopsies could provide efficient and less invasive options for detection and monitoring. The market is inherently dynamic and innovation-driven, with shifts towards personalized healthcare and technological integration. Business growth can be significantly propelled by leveraging partnerships with academic institutions for research collaborations and focusing on cost-effective solutions that enhance accessibility. Companies that invest in R&D and capitalize on growing consumer awareness while addressing affordability issues might achieve a competitive edge. Navigating regulatory pathways effectively and enhancing the scope of genetic testing could further solidify market leadership.

Understanding Market Dynamics in the Ovarian Cancer Diagnostics Market

The Ovarian Cancer Diagnostics Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing favorable government initiatives and growing funding for ovarian cancer research
    • Growing prevalence of ovarian cancer among women worldwide
    • Potential demand for early diagnosis and treatment
  • Market Restraints
    • Relatively high cost of diagnosis and concerns of adverse effects of the treatment among patients
  • Market Opportunities
    • Emerging modernization and advancements in technical diagnostic tools for ovarian cancer
    • Ongoing application of combination therapies to treat ovarian cancer
  • Market Challenges
    • Reduced awareness and dearth of precise diagnosis of ovarian cancer

Exploring Porter’s Five Forces for the Ovarian Cancer Diagnostics Market

Porter’s Five Forces framework further strengthens the insights of the Ovarian Cancer Diagnostics Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Ovarian Cancer Diagnostics Market

External macro-environmental factors deeply influence the performance of the Ovarian Cancer Diagnostics Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Ovarian Cancer Diagnostics Market

The Ovarian Cancer Diagnostics Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Ovarian Cancer Diagnostics Market

The Ovarian Cancer Diagnostics Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Ovarian Cancer Diagnostics Market

The Ovarian Cancer Diagnostics Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Ovarian Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories Ltd., Almac Group, Apollo Diagnostics, AstraZeneca PLC, Avalon Health Economics LLC, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Laboratory Corporation of America Holdings, MedGenome Labs Ltd., Myriad Genetics Inc., Oncgnostics GmbH, Ovation Diagnostics LLC, Pfizer, Inc., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Ovarian Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Cancer Type
    • Epithelial Tumor
    • Germ Cell Tumor
    • Stromal Cell Tumor
  • Diagnosis Type
    • Biopsy
    • Blood Test
      • BRCA
      • CA125
      • CEA
      • ER & PR
      • HER2
      • KRAS Mutation
    • Imaging
      • CT Scan
      • MRI Scan
      • PET Scan
      • Ultrasound
  • End-User
    • Cancer Diagnostic Centers
    • Hospital Laboratories
    • Research Institutes
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing favorable government initiatives and growing funding for ovarian cancer research
5.1.1.2. Growing prevalence of ovarian cancer among women worldwide
5.1.1.3. Potential demand for early diagnosis and treatment
5.1.2. Restraints
5.1.2.1. Relatively high cost of diagnosis and concerns of adverse effects of the treatment among patients
5.1.3. Opportunities
5.1.3.1. Emerging modernization and advancements in technical diagnostic tools for ovarian cancer
5.1.3.2. Ongoing application of combination therapies to treat ovarian cancer
5.1.4. Challenges
5.1.4.1. Reduced awareness and dearth of precise diagnosis of ovarian cancer
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Ovarian Cancer Diagnostics Market, by Cancer Type
6.1. Introduction
6.2. Epithelial Tumor
6.3. Germ Cell Tumor
6.4. Stromal Cell Tumor
7. Ovarian Cancer Diagnostics Market, by Diagnosis Type
7.1. Introduction
7.2. Biopsy
7.3. Blood Test
7.3.1. BRCA
7.3.2. CA125
7.3.3. CEA
7.3.4. ER & PR
7.3.5. HER2
7.3.6. KRAS Mutation
7.4. Imaging
7.4.1. CT Scan
7.4.2. MRI Scan
7.4.3. PET Scan
7.4.4. Ultrasound
8. Ovarian Cancer Diagnostics Market, by End-User
8.1. Introduction
8.2. Cancer Diagnostic Centers
8.3. Hospital Laboratories
8.4. Research Institutes
9. Americas Ovarian Cancer Diagnostics Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Ovarian Cancer Diagnostics Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Ovarian Cancer Diagnostics Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. OVARIAN CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
FIGURE 2. OVARIAN CANCER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 11. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. OVARIAN CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. OVARIAN CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. OVARIAN CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. OVARIAN CANCER DIAGNOSTICS MARKET DYNAMICS
TABLE 7. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY EPITHELIAL TUMOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY GERM CELL TUMOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY STROMAL CELL TUMOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BRCA, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CA125, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CEA, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY ER & PR, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY HER2, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY KRAS MUTATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY MRI SCAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY PET SCAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 45. BRAZIL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 46. BRAZIL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 47. CANADA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 48. CANADA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 49. CANADA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 50. CANADA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 51. CANADA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 52. MEXICO OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 53. MEXICO OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 54. MEXICO OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 55. MEXICO OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 56. MEXICO OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 66. ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 67. ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 68. ASIA-PACIFIC OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 69. AUSTRALIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 70. AUSTRALIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 71. AUSTRALIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 72. AUSTRALIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 73. AUSTRALIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 74. CHINA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 75. CHINA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 76. CHINA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 77. CHINA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 78. CHINA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 79. INDIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 80. INDIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 81. INDIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 82. INDIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 83. INDIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 84. INDONESIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 85. INDONESIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 86. INDONESIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 87. INDONESIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 88. INDONESIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 89. JAPAN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 90. JAPAN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 91. JAPAN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 92. JAPAN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 93. JAPAN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 94. MALAYSIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 95. MALAYSIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 96. MALAYSIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 97. MALAYSIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 98. MALAYSIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 99. PHILIPPINES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 100. PHILIPPINES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 101. PHILIPPINES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 102. PHILIPPINES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 103. PHILIPPINES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 104. SINGAPORE OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 105. SINGAPORE OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 106. SINGAPORE OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 107. SINGAPORE OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 108. SINGAPORE OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 109. SOUTH KOREA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 110. SOUTH KOREA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 111. SOUTH KOREA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 112. SOUTH KOREA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 113. SOUTH KOREA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 114. TAIWAN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 115. TAIWAN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 116. TAIWAN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 117. TAIWAN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 118. TAIWAN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 119. THAILAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 120. THAILAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 121. THAILAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 122. THAILAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 123. THAILAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 124. VIETNAM OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 125. VIETNAM OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 126. VIETNAM OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 127. VIETNAM OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 128. VIETNAM OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 135. DENMARK OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 136. DENMARK OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 137. DENMARK OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 138. DENMARK OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 139. DENMARK OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 140. EGYPT OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 141. EGYPT OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 142. EGYPT OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 143. EGYPT OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 144. EGYPT OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 145. FINLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 146. FINLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 147. FINLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 148. FINLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 149. FINLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 150. FRANCE OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 151. FRANCE OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 152. FRANCE OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 153. FRANCE OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 154. FRANCE OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 155. GERMANY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 156. GERMANY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 157. GERMANY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 158. GERMANY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 159. GERMANY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 160. ISRAEL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 161. ISRAEL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 162. ISRAEL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 163. ISRAEL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 164. ISRAEL OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 165. ITALY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 166. ITALY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 167. ITALY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 168. ITALY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 169. ITALY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 170. NETHERLANDS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 171. NETHERLANDS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 172. NETHERLANDS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 173. NETHERLANDS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 174. NETHERLANDS OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 175. NIGERIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 176. NIGERIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 177. NIGERIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 178. NIGERIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 179. NIGERIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 180. NORWAY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 181. NORWAY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 182. NORWAY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 183. NORWAY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 184. NORWAY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 185. POLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 186. POLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 187. POLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 188. POLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 189. POLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 190. QATAR OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 191. QATAR OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 192. QATAR OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 193. QATAR OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 194. QATAR OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 204. SAUDI ARABIA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 208. SOUTH AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 210. SPAIN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 211. SPAIN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 212. SPAIN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 213. SPAIN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 214. SPAIN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 215. SWEDEN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 216. SWEDEN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 217. SWEDEN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 218. SWEDEN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 219. SWEDEN OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 220. SWITZERLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 221. SWITZERLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 222. SWITZERLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 223. SWITZERLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 224. SWITZERLAND OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 225. TURKEY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 226. TURKEY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 227. TURKEY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 228. TURKEY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 229. TURKEY OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 236. UNITED KINGDOM OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 238. UNITED KINGDOM OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM OVARIAN CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 240. OVARIAN CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 241. OVARIAN CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Ovarian Cancer Diagnostics Market, which are profiled in this report, include:
  • Abbott Laboratories Ltd.
  • Almac Group
  • Apollo Diagnostics
  • AstraZeneca PLC
  • Avalon Health Economics LLC
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Laboratory Corporation of America Holdings
  • MedGenome Labs Ltd.
  • Myriad Genetics Inc.
  • Oncgnostics GmbH
  • Ovation Diagnostics LLC
  • Pfizer, Inc.
  • Thermo Fisher Scientific Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages190
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 8.18 Billion
Forecasted Market Value ( USD ) by 2030 $ 18.5 Billion
Compound Annual Growth Rate14.5%
Regions CoveredGlobal
No. of Companies Mentioned16

Related Topics

Related Reports

Ovarian Cancer Diagnostics And Therapeutics Market Report and Forecast 2024-2032 - Product Image

Ovarian Cancer Diagnostics And Therapeutics Market Report and Forecast 2024-2032

  • Report
  • 195 Pages
  • Global
From
Ovarian Cancer Diagnostics Market Analysis & Forecast to 2024-2034 - Product Image

Ovarian Cancer Diagnostics Market Analysis & Forecast to 2024-2034

  • Report
  • 200 Pages
  • Global
From
Ovarian Cancer Diagnostics Global Market Report 2024 - Product Image

Ovarian Cancer Diagnostics Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Advanced Recurrent Ovarian Cancer Market by Disease Type, Treatment Type - Global Forecast 2025-2030 - Product Image

Advanced Recurrent Ovarian Cancer Market by Disease Type, Treatment Type - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Ovarian Cancer Market by Type, by Diagnosis Scans, by Treatment, by End-user, and by Region - Product Image

Ovarian Cancer Market by Type, by Diagnosis Scans, by Treatment, by End-user, and by Region

  • Report
  • 200 Pages
  • Global
From

About the Ovarian Cancer Diagnostics Market

The ovarian cancer diagnostics market encompasses a range of medical devices, laboratory tests, and software used for the detection and diagnosis of ovarian cancer, one of the most common types of cancer affecting the female reproductive system. Within the broader diagnostics sector, ovarian cancer diagnostics represent an important niche focused on early detection, accurate staging, and determination of the specific ovarian cancer subtype, which is crucial for effective treatment planning and improved patient outcomes. Ovarian cancer diagnosis typically begins with a clinical examination followed by a series of tests. These may include imaging tests like ultrasounds and MRIs, blood tests for cancer markers, genetic testing for hereditary cancer syndromes, and biopsy procedures for histological analysis. The development of more advanced diagnostics, such as liquid biopsies and next-generation genomic sequencing, aims to enhance the precision and ease of detection, providing clinicians with more detailed information about the disease. Companies active in the ovarian cancer diagnostics market specialize in different aspects of the diagnostic process. Some notable players include Roche Diagnostics, which offers a range of assays and testing platforms; Agilent Technologies, known for their advanced pathology and genomics solutions; Siemens Healthineers, providing imaging equipment and laboratory diagnostics; and Myriad Genetics, which focuses on genetic tests for assessing cancer risks and guiding treatment decisions. These companies, along with others in the field, contribute to ongoing advancements in ovarian cancer detection and management. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.